OLN324: Why Size May Matter - Report - MDSpire

OLN324: Why Size May Matter

David A. Eichenbaum, MD, FASRS, and Veeral S. Sheth, MD, MBA, discuss phase 1 JADE findings and how OLN324's small-format design may contribute to improved retinal drying in nAMD and diabetic macular edema.

  • By

  • David A. Eichenbaum, MD

  • Veeral S. Sheth, MD, MBA, FACS

  • July 15, 2026

  • 3 min

Share

Clinical Report: OLN324: Why Size May Matter

Overview

The phase 1 JADE study indicates that OLN324 may provide retinal drying in nAMD and diabetic macular edema compared to faricimab. OLN324 demonstrated a higher percentage of DME resolution and greater visual acuity gains in AMD patients.

Background

The management of exudative retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) is critical for preserving vision. Current standards of care primarily involve anti-VEGF therapies. The introduction of new agents like OLN324, which features a small-format design, may enhance treatment efficacy.

Data Highlights

OutcomeOLN324Faricimab
DME Resolution at Week 1250% moreReference
Visual Acuity Gain in AMD+2.2 lettersReference
Intraocular InflammationNoneReference

Key Findings

  • OLN324 showed better retinal drying compared to faricimab in DME patients.
  • A higher percentage of OLN324 patients achieved DME resolution at week 12.
  • In AMD, OLN324 demonstrated a gain of 2.2 letters in visual acuity compared to faricimab.
  • OLN324 resulted in earlier and more significant flattening of pigment epithelial detachments (PEDs).
  • No intraocular inflammation or vascular occlusions were reported in OLN324 patients.

Clinical Implications

Clinicians should consider the bispecific antibody OLN324 in treatment-naïve and previously treated patients.

Conclusion

OLN324's phase 1 results indicate its potential for further investigation in phase 3 trials.

Related Resources & Content

  1. American Academy of Ophthalmology, 2024/2025 Age-Related Macular Degeneration Preferred Practice Pattern
  2. JAMA Ophthalmology, 2026 - Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration
  3. Ophthalmology Management — viewpoint
  4. Eyecare Business — Ordering Problems and Solutions
  5. Eyecare Business — The Large and Small of It
  6. Ophthalmology Management — Sizing Up Your Biometry Options
  7. Ophthalmology Management — viewpoint
  8. Eyecare Business — Ordering Problems and Solutions
  9. Eyecare Business — The Large and Small of It
  10. Age-Related Macular Degeneration Preferred Practice Pattern® - Ophthalmology
  11. Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration | Trials | JAMA Ophthalmology | JAMA Network
  12. Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration - PMC

Original Source(s)

OLN324: Why Size May Matter

  • by David A. Eichenbaum, MD, Veeral S. Sheth, MD, MBA, FACS

  • July 15, 2026

Related Content

Can Stem Cell Therapy Slow GA?

Phase 1b data for ASP7317, presented at ASRS, showed a favorable safety profile, encouraging visual acuity findings, and stabilization of geographic atrophy in patients with advanced disease.

OTX-TKI: Inside the SOL-1 Data

At ASRS 2026, Dilsher S. Dhoot, MD, FASRS, shared additional phase 3 SOL-1 data on vision maintenance, rescue treatment, and safety with investigational OTX-TKI (Axpaxli) in neovascular AMD.

Elevated GDF15 in ocular fluids of patients with proliferative diabetic retinopathy